Suppliers / Pfizer Brasil Ltda

Pfizer Brasil Ltda

Mexico Updated 9 July 2026

Pfizer Brasil Ltda is an API and finished-dose manufacturer based in Mexico. It holds 4 valid CEPs across a filed portfolio of 3 molecules. Its filings concentrate with MEDSAFE (NZ), US FDA and ANVISA (Brazil). Its GMP standing is certified by ANVISA (Brazil), EAEU_EEC and BPOM (ID), among 15 authorities. Its most recent recorded inspection, by US FDA, closed on 13 May 2025 as VAI.

0
active US DMFs
4
valid CEPs
12
registered plants
7,277
filings across 46 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
0 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 13 May 2025 VAI US FDA
  • 7 February 2025 NAI US FDA
  • 20 January 2025 NAI US FDA
  • 17 January 2025 VAI US FDA
  • 1 November 2024 NAI US FDA
  • 25 October 2024 VAI US FDA
  • 2 May 2024 NAI US FDA
  • 1 May 2024 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Alcorcon Not on file
Mulgrave Not on file
Puurs Sint Amands Not on file
Puurs Not on file
Freiburg Not on file
PUURS Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Methylprednisolone EDQM 2
Hydrocortisone EDQM 1
Piroxicam EDQM 1

Also appears on these molecule pages

Show 76 more molecule pages
Carboplatin finished dose Celecoxib finished dose Chlorpromazine finished dose Chlorthalidone finished dose Ciprofloxacin finished dose Clindamycin finished dose Daptomycin finished dose Desogestrel finished dose Desvenlafaxine finished dose Dextromethorphan finished dose Diazepam finished dose Digoxin finished dose Diltiazem finished dose Dimenhydrinate finished dose Diphenhydramine finished dose Doxazosin finished dose Doxycycline finished dose Drospirenone finished dose Eplerenone finished dose Erythromycin finished dose Estradiol finished dose Ethinylestradiol finished dose Fluconazole finished dose Furosemide finished dose Gentamicin finished dose Glibenclamide finished dose Guaifenesin finished dose Heparin finished dose Hydrocortisone API Hydroxyzine finished dose Latanoprost finished dose Levetiracetam finished dose Levonorgestrel finished dose Lidocaine finished dose Lorazepam finished dose Mefenamic Acid finished dose Meprobamate finished dose Meropenem finished dose Methylprednisolone API Metronidazole finished dose Midazolam finished dose Minoxidil finished dose Naltrexone finished dose Neomycin finished dose Nicotine finished dose Nifedipine finished dose Nitrofurantoin finished dose Norethisterone finished dose Olmesartan Medoxomil finished dose Ondansetron finished dose Paclitaxel finished dose Phenytoin finished dose Piperacillin finished dose Piroxicam API Polymyxin B finished dose Prednisolone finished dose Propofol finished dose Propranolol finished dose Pseudoephedrine finished dose Quetiapine finished dose Ritonavir finished dose Scopolamine finished dose Sertraline finished dose Sildenafil finished dose Spironolactone finished dose Sulbactam finished dose Sulfamethoxazole finished dose Tamoxifen finished dose Tazobactam finished dose Tetracycline finished dose Tinidazole finished dose Tobramycin finished dose Trimethoprim finished dose Venlafaxine finished dose Verapamil finished dose Zolpidem finished dose

Filings and GMP by regulator

Regulator Filings GMP certificates
MEDSAFE (NZ) 952 None
US FDA 754 10
ANVISA (Brazil) 629 30
Health Canada 629 None
INHRR (VE) 619 None
EMA 616 12
EAEU_EEC None 18
BPOM (ID) None 16
MFDS (Korea) None 6
ZLG (DE) None 4
MHRA (UK) None 4
NAFDAC (NG) None 3
INFARMED (PT) None 2
HSA (SG) None 2
COFEPRIS (MX) None 2
AEMPS (ES) None 1
NCELS (KZ) None 1
TMDA (TZ) None 1

Scale

Year Revenue Exports Destinations
2024 $960.0B Not reported Not reported
2023 $970.0B Not reported Not reported
2022 $930.0B Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Pfizer Brasil Ltda comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 100 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 13 May 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported